Centre for Behavioral Sciences and Mental Health, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161, Rome, Italy.
National Centre for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Intern Emerg Med. 2023 Apr;18(3):733-741. doi: 10.1007/s11739-022-03169-5. Epub 2023 Feb 2.
The management of acute chest pain is one of the challenges for emergency departments (EDs) worldwide. This study aims to provide insights into clinical and organizational aspects related to the use of different cardiac troponin tests for the diagnosis of NSTEMI. A prospective observational study was conducted among 12 Italian EDs. Eligible participants had chest pain of suspected cardiac origin and accessed EDs from January 2017 to March 2019. A 30-day follow-up was performed to gather information about the main cardiac outcomes. Tests validity and performance were assessed by computing sensitivity, specificity, positive and negative predictive values and area under the ROC curve. The independent association between adverse event end point at 30 days and type of troponin was evaluated by multiple logistic regression models, using odds ratio and 95% confidence interval. 2913 patients were included. Almost 72% were affected by comorbidities and most of them stayed in the EDs for more than 3 h, with significant differences among the different troponin assays. The results of follow-up at 30 days for the outcomes considered for the patients who were ruled out in 3 h or less did not differ significantly compared to those ruled out after 3 h or more. After adjustment for confounders, patients admitted to an ED that used a high-sensitivity troponin were at a lower risk of having a MACE (OR = 0.53, 95%CI 0.35-0.90) and a non-significant lower risk of myocardial infarction (OR = 0.68, 95% CI 0.41-1.13, p = 0.1314) at 30 days compared to patients admitted to an ED that used a standard troponin. Appropriate troponin testing is extremely important for differential diagnosis and for addressing proper treatment and safe procedures for patients who are not admitted to the hospital.
急性胸痛的管理是全球急诊科面临的挑战之一。本研究旨在深入了解与使用不同的心脏肌钙蛋白检测用于诊断非 ST 段抬高型心肌梗死(NSTEMI)相关的临床和组织方面。在意大利的 12 家急诊科进行了一项前瞻性观察性研究。符合条件的参与者具有疑似心源性胸痛,并于 2017 年 1 月至 2019 年 3 月期间就诊于急诊科。进行了 30 天随访,以收集主要心脏结局的信息。通过计算敏感性、特异性、阳性和阴性预测值以及 ROC 曲线下面积来评估检测的有效性和性能。通过多因素逻辑回归模型,使用比值比和 95%置信区间评估 30 天不良事件终点与肌钙蛋白类型之间的独立关联。共纳入 2913 例患者。近 72%的患者患有合并症,其中大多数在急诊科停留时间超过 3 小时,不同肌钙蛋白检测之间存在显著差异。在 3 小时或更短时间内排除的患者与 3 小时或更长时间后排除的患者相比,考虑排除的患者 30 天随访的结果没有显著差异。在校正混杂因素后,与在使用常规肌钙蛋白的急诊科就诊的患者相比,在使用高敏肌钙蛋白的急诊科就诊的患者发生主要不良心脏事件(MACE)(OR=0.53,95%CI 0.35-0.90)和心肌梗死(OR=0.68,95%CI 0.41-1.13,p=0.1314)的风险较低。适当的肌钙蛋白检测对于鉴别诊断以及为未住院的患者提供适当的治疗和安全程序非常重要。